Skip to Main Content

Author Details

Ronald Simon
Institute of Pathology, University Medical Center Hamburg-Eppendorf
1996
447
70
PMIDPaper TitleJournal TitlePublished Year
37777995Loss of Upk1a and Upk1b expression is linked to stage progression in urothelial carcinoma of the bladder.Int Urol Nephrol2024
37951531Comparison of INSM1 immunostaining with established neuroendocrine markers synaptophysin and chromogranin A in over 14,000 neuroendocrine and non-neuroendocrine tumors.Mol Cell Endocrinol2024
35946088Pan-keratin Immunostaining in Human Tumors: A Tissue Microarray Study of 15,940 Tumors.Int J Surg Pathol2023
37558687Cadherin-16 (CDH16) immunohistochemistry: a useful diagnostic tool for renal cell carcinoma and papillary carcinomas of the thyroid.Sci Rep2023
37892063Diagnostic Role and Prognostic Impact of PSAP Immunohistochemistry: A Tissue Microarray Study on 31,358 Cancer Tissues.Diagnostics (Basel)2023
37938166Altered p53/p16 expression is linked to urothelial carcinoma progression but largely unrelated to prognosis in muscle-invasive tumors.Acta Oncol2023
37644036Loss of LCMT1 and biased protein phosphatase 2A heterotrimerization drive prostate cancer progression and therapy resistance.Nat Commun2023
37057870Pattern of MUC6 expression across 119 different tumor types: A tissue microarray study on 15â¿¿412 tumors.Pathol Int2023
37179317An exploratory study for tuft cells in the breast and their relevance in triple-negative breast cancer: the possible relationship of SOX9.BMC Cancer2023
36980510Mammaglobin-A Expression Is Highly Specific for Tumors Derived from the Breast, the Female Genital Tract, and the Salivary Gland.Diagnostics (Basel)2023
37379306CELA3B immunostaining is a highly specific marker for acinar cell carcinoma of the pancreas.PLoS One2023
36976297BLEACH&STAIN 15-marker Multiplexed Imaging in 3,098 Human Carcinomas Reveals Six Major PD-L1-driven Immune Phenotypes with Distinct Spatial Orchestration.Mol Cancer Res2023
36997051Cytokeratin 20 expression is linked to stage progression and to poor prognosis in advanced (pT4) urothelial carcinoma of the bladder.Exp Mol Pathol2023
36656126Automated Ki-67 labeling index assessment in prostate cancer using artificial intelligence and multiplex fluorescence immunohistochemistry.J Pathol2023
36788088Nonredundant Upregulation of CD112R (PVRIG) and PD-1 on Cytotoxic T Lymphocytes Located in T Cell Nests of Colorectal Cancer.Mod Pathol2023
36649695GATA3 Expression in Human Tumors: A Tissue Microarray Study on 16,557 Tumors.Pathobiology2023
36644936Peripheral and Portal Venous KRAS ctDNA Detection as Independent Prognostic Markers of Early Tumor Recurrence in Pancreatic Ductal Adenocarcinoma.Clin Chem2023
36683495PD-L1 expression and CD8 positive lymphocytes in human neoplasms: A tissue microarray study on 11,838 tumor samples.Cancer Biomark2023
36728364High Homogeneity of Mesothelin Expression in Primary and Metastatic Ovarian Cancer.Appl Immunohistochem Mol Morphol2023
36269681Cytokeratin 13 (CK13) expression in cancer: a tissue microarray study on 10,439 tumors.APMIS2023
35917493SATB2 Expression in Human Tumors: A Tissue Microarray Study on More Than 15â¿¿000 Tumors.Arch Pathol Lab Med2023
33414516CHD1 loss negatively influences metastasis-free survival in R0-resected prostate cancer patients and promotes spontaneous metastasis in vivo.Cancer Gene Ther2022
35550834Large-scale human tissue analysis identifies Uroplakin 1b as a putative diagnostic marker in surgical pathology.Hum Pathol2022
35477165Trophoblast Cell Surface Antigen 2 Expression in Human Tumors: A Tissue Microarray Study on 18,563 Tumors.Pathobiology2022
35764407Mucin 5AC expression is common but unrelated to tumor progression in pancreatic adenocarcinoma.Int J Immunopathol Pharmacol2022
35642329DOG1 overexpression is associated with mismatch repair deficiency and BRAF mutations but unrelated to cancer progression in colorectal cancer.Histol Histopathol2022
35606285Reduced CDH16 expression is linked to poor prognosis in clear cell renal cell carcinoma 16.Urol Oncol2022
35390310Cytokeratin 7 and cytokeratin 20 expression in cancer: A tissue microarray study on 15,424 cancers.Exp Mol Pathol2022
35862385High prevalence of p16 staining in malignant tumors.PLoS One2022
35449481Correction to: MMR Deficiency is Homogeneous in Pancreatic Carcinoma and Associated with High Density of Cd8-Positive Lymphocytes.Ann Surg Oncol2022
35872365Large-scale human tissue analysis identifies Uroplakin 1a as a putative diagnostic marker for urothelial cancer.Pathol Res Pract2022
35999270Tuft cell-like carcinomas: novel cancer subsets present in multiple organs sharing a unique gene expression signature.Br J Cancer2022
36137400Diagnostic and prognostic role of pancreatic secretory granule membrane major glycoprotein 2 (GP2) immunohistochemistry: A TMA study on 27,681 tumors.Pathol Res Pract2022
35866621Villin expression in human tumors: a tissue microarray study on 14,398 tumors.Expert Rev Mol Diagn2022
35992051Diagnostic and Prognostic Impact of Progesterone Receptor Immunohistochemistry: A Study Evaluating More Than 16,000 Tumors.Anal Cell Pathol (Amst)2022
36029589Cytokeratin 10 (CK10) expression in cancer: A tissue microarray study on 11,021 tumors.Ann Diagn Pathol2022
36292206Analysis of More than 16,000 Human Tumor and Normal Tissues Identifies Uroplakin 3B as a Useful Diagnostic Marker for Mesothelioma and Normal Mesothelial Cells.Diagnostics (Basel)2022
35921917Synaptophysin and chromogranin A expression analysis in human tumors.Mol Cell Endocrinol2022
36289769Inhibin Alpha Expression in Human Tumors: A Tissue Microarray Study on 12,212 Tumors.Biomedicines2022
35951102FABP1 expression in human tumors: a tissue microarray study on 17,071 tumors.Virchows Arch2022
35920686Estrogen Receptor Alpha Gene Amplification Is an Independent Predictor of Long-Term Outcome in Postmenopausal Patients with Endocrine-Responsive Early Breast Cancer.Clin Cancer Res2022
36152841GATA3 expression loss is linked to stage progression but is unrelated to prognosis in muscle-invasive urothelial carcinoma of the bladder.Hum Pathol2022
36077784T-Cell Density at the Invasive Margin and Immune Phenotypes Predict Outcome in Vulvar Squamous Cell Cancer.Cancers (Basel)2022
36375372Desmoglein 3 (Dsg3) expression in cancer: A tissue microarray study on 15,869 tumors.Pathol Res Pract2022
34889867Carboxypeptidase A1 (CPA1) Immunohistochemistry Is Highly Sensitive and Specific for Acinar Cell Carcinoma (ACC) of the Pancreas.Am J Surg Pathol2022
35091676Semi-automated validation and quantification of CTLA-4 in 90 different tumor entities using multiple antibodies and artificial intelligence.Lab Invest2022
35267575PITX1 Is a Regulator of TERT Expression in Prostate Cancer with Prognostic Power.Cancers (Basel)2022
346259096q deletion is frequent but unrelated to patient prognosis in breast cancer.Breast Cancer2022
34559291Cytokeratin 5 and cytokeratin 6 expressions are unconnected in normal and cancerous tissues and have separate diagnostic implications.Virchows Arch2022
32303902High level of EZH2 expression is linked to high density of CD8-positive T-lymphocytes and an aggressive phenotype in renal cell carcinoma.World J Urol2021
  • 1 - 50 of 447

Recommended Authors

University of Basel
Career Start Year 2008
Number of shared co-authors 8
University of California San Francisco.
Career Start Year 2007
Number of shared co-authors 3
Institute for Pathology, University Hospital Schleswig-Holstein
Career Start Year 2007
Number of shared co-authors 5
Centre hospitalier de l'Universite de Montreal
Career Start Year 2006
Number of shared co-authors 7
University of Turin, Candiolo Cancer Institute, FPO-IRCCS
Career Start Year 2005
Number of shared co-authors 5
The First Affiliated Hospital of Jinan University
Career Start Year 2004
Number of shared co-authors 2
Caryl and Israel Englander Institute for Precision Medicine
Career Start Year 2002
Number of shared co-authors 9
Olivia Newton-John Cancer Research Institute
Career Start Year 2002
Number of shared co-authors 1
The Institute of Cancer Research
Career Start Year 2002
Number of shared co-authors 5
University of Alabama at Birmingham, USA O'Neal Comprehensive Cancer Center
Career Start Year 2001
Number of shared co-authors 4
Meyer Cancer Center
Career Start Year 2001
Number of shared co-authors 8
Institut fur Pathologie, Universitatsmedizin Mannheim
Career Start Year 2000
Number of shared co-authors 4
Institute for Computational Biomedicine
Career Start Year 2000
Number of shared co-authors 10
Institute of Pathology, University Hospital Heidelberg
Career Start Year 1996
Number of shared co-authors 9
Memorial Sloan-Kettering Cancer Center
Career Start Year 1996
Number of shared co-authors 12
The Francis Crick Institute
Career Start Year 1994
Number of shared co-authors 0
Barts Cancer Institute, Queen Mary University of London
Career Start Year 1993
Number of shared co-authors 9
Georgetown University
Career Start Year 1993
Number of shared co-authors 0
University of Edinburgh
Career Start Year 1992
Number of shared co-authors 8
Cancer Research UK Cambridge Institute, University of Cambridge
Career Start Year 1992
Number of shared co-authors 10
Institutet of Bioinformatics, University Hospital of Munster, University of Munster
Career Start Year 1990
Number of shared co-authors 3
Vattikuti Urology Institute
Career Start Year 1990
Number of shared co-authors 6
Norwich Medical School, University of East Anglia
Career Start Year 1989
Number of shared co-authors 3
Center for Cancer Research, National Cancer Institute
Career Start Year 1988
Number of shared co-authors 2
University of British Columbia
Career Start Year 1988
Number of shared co-authors 19
Stanford University School of Medicine
Career Start Year 1987
Number of shared co-authors 1
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Career Start Year 1986
Number of shared co-authors 0
Karolinska Institute
Career Start Year 1984
Number of shared co-authors 13
Foundation Medicine
Career Start Year 1974
Number of shared co-authors 6
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 1970
Number of shared co-authors 8

Collaborators

Institute of Pathology, University Medical Center Hamburg-Eppendorf
Co-authored papers 377
Institute of Pathology, University Medical Center Hamburg-Eppendorf
Co-authored papers 148
Charite - University Hospital Berlin
Co-authored papers 144
Institute of Pathology, University Medical Center Hamburg-Eppendorf
Co-authored papers 136
University Hospital Frankfurt, Goethe University Frankfurt am Main
Co-authored papers 102
Martini-Klinik Prostate Cancer Center, University Hospital-Hamburg-Eppendorf
Co-authored papers 91
Institute of Pathology, University Medical Center Hamburg-Eppendorf
Co-authored papers 78
University Medical Center Hamburg-Eppendorf
Co-authored papers 14
European Bioinformatics Institute (EMBL-EBI)
Co-authored papers 11
German Cancer Research Center
Co-authored papers 11
University Hospital Zurich
Co-authored papers 9
University of Copenhagen
Co-authored papers 9
University Medical Center Hamburg-Eppendorf
Co-authored papers 8
German Cancer Research Center (DKFZ)
Co-authored papers 7
University Hospital
Co-authored papers 6
University Medical Center Utrecht
Co-authored papers 5
Co-authored papers 5
Central Finland Hospital Nova
Co-authored papers 5
German Cancer Research Center (DKFZ)
Co-authored papers 5
German Cancer Research Center (DKFZ)
Co-authored papers 5
German Cancer Research Center (DKFZ)
Co-authored papers 3
Pathologisches Institut, Universitatsklinikum Heidelberg
Co-authored papers 3
Berlin Institute of Health (BIH) and Charite
Co-authored papers 3
German Cancer Research Center (DKFZ)
Co-authored papers 3
Institute for Human Genetics, University of Wurzburg
Co-authored papers 3
Universitatsklinikum Hamburg-Eppendorf
Co-authored papers 3
Max Planck Institute for Molecular Genetics
Co-authored papers 3
German Cancer Research Center (DKFZ)
Co-authored papers 3
German Cancer Research Center
Co-authored papers 3
Max-Planck-Institute for Molecular Genetics
Co-authored papers 2